Essential Medicines Initiative

Advancing essential medicines for critical care scenarios where current options are limited, compromised, or don't yet exist.

Programmable Glycan Design and Synthesis

Glycan Engineering| CellFlow

Structurally defined glycans with enzymatic precision at synthetic speed.

Deployment

Our Focus in Essential Medicines

Acute Care

Acute Care

Hospital & critical care settings

  • Inpatient prophylaxis & treatment
  • ICU, surgical, & emergency care
  • Interventional & procedural support
Outpatient

Outpatient

Community & chronic care

  • Post-discharge continuation therapy
  • Chronic & episodic treatment
  • Home-administered regimens
Preparedness

Preparedness

Strategic stockpile & field deployment

  • Strategic national stockpile
  • Forward & field deployment
  • Mass casualty surgical triage
Pipeline

Our Programs

BIOX-1

Bioxaparin™Pioneering synthetic heparin

The world's most prescribed anticoagulant depends on a single animal-derived supply chain.
We engineered the synthetic alternative — improving supply security and patient safety.

12M+

patients treated annually

in the U.S.

80%

API production in China

single-source dependency

100+

deaths from contaminated heparin

2008 crisis
1B+

pigs required per year

global supply chain

An essential medicine,

Our biosynthetic process emulates heparin's natural pathway through four sequential in vitro enzymatic steps — delivering a molecule structurally and functionally equivalent to Lovenox®.

Structural & functional equivalence to Lovenox®
Anticoagulant potency validated (Anti-Xa, Anti-IIa)
Animal-free, tunable composition
Distributed & Population-scale manufacturing
Historical Precedent

The Insulin Story

% Insulin Volume Split by Type

0%25%50%75%100%198219861990199419982002200620102014
Animal InsulinRecombinant InsulinRecombinant Insulin Analogue

Source: RethinkX, IMS Health, Washington Post, Novo Nordisk

Discovery & First Use

Insulin was discovered in the 1920s and produced from cattle pancreases for decades.

Recombinant Production

In 1982, the FDA approved Genentech’s synthetic human insulin — made from recombinant DNA, not animal tissue.

The Parallel

Within a decade, recombinant insulin became standard of care globally. Opening up the path to improved analog versions.

BIOX-2

Tissue Repair & Regeneration

Heparin-Mimetic for prevention of acute organ/tissue damage

1The Problem

Acute organ damage destroys the endothelial and epithelial barriers that protect every organ.

Once compromised, fluid leaks, inflammation cascades, and tissue dies. From ARDS to sepsis to radiation injury — there are no approved therapies that directly restore these barriers.

2The Molecule

A non-anticoagulant heparan sulfate mimetic engineered to restore barrier function across organs.

Stabilizes growth factors (FGF, VEGF)accelerates repair

Preserves glycocalyx barrierprotects epithelium and endothelium

Neutralizes DAMPs & histonesdampens inflammation

Inhibits heparanaseprevents ECM breakdown & fibrosis

Acute Respiratory Distress Syndrome
Lead Indication

Acute Respiratory Distress Syndrome

ARDS destroys the alveolar-capillary barrier, causing fluid to flood the lungs. BIOX-2 stabilizes the endothelial glycocalyx to restore barrier integrity and protect lung tissue.

VOD/SOS Prophylaxis
Lead Indication

VOD/SOS Prophylaxis

Veno-occlusive disease damages the hepatic sinusoidal lining after bone marrow conditioning. BIOX-2 protects the liver endothelium during transplant conditioning to prevent barrier breakdown.

Sepsis & Systemic Inflammation
Expansion

Sepsis & Systemic Inflammation

Sepsis degrades the glycocalyx systemically, causing vascular leak and cytokine-driven injury across organs. BIOX-2 neutralizes histones and DAMPs to dampen the inflammatory cascade.

Radiation-Induced GI Damage
Expansion

Radiation-Induced GI Damage

GI mucositis after radiation or nuclear exposure destroys the gut lining. BIOX-2 preserves epithelial tight junctions and accelerates mucosal repair of the intestinal barrier.

Manufacturing

CellFlow Scale-Up

Manufacturing facility

CellFlow Synthesis

U.S. Expansion with Partners

Distributed, scalable manufacturing — from factory floor to forward deployment.

  • High-purity, modular scale-up
  • Unprecedented biomolecule design space
  • Precise control of branching, sulfation, and epimerization

Other Approaches

Chemical Synthesis

Limited design space, harsh reagents, expensive

Animal Extraction

Inconsistent structures, supply risk

Recombinant Production

Imprecise glycan control, low yields

Bioreactor system
Get In Touch

Connect with us